SAN DIEGO, April 27, 2010 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Annual
Meeting of Stockholders on Thursday, April
29, 2010 at 9:00 a.m. PT/
12:00 p.m. ET from the Company's
corporate headquarters in San Diego,
CA. Following the Annual Meeting, Daniel M. Bradbury, president and chief
executive officer of Amylin Pharmaceuticals, will provide a
corporate overview.
To access the webcast, please log on to the "Investors" section
of Amylin's corporate Web site at www.amylin.com approximately
fifteen minutes prior to the call to register, download and install
any necessary audio software. For those without access to the
Internet, the live call may be accessed by phone by calling (866)
202-0886 (U.S./Canada) or (617)
213-8841(international), participant passcode# 47522587. A replay
of the call will also be available by phone beginning approximately
two hours after the close of the call and can be accessed at (888)
286-8010 (U.S./Canada) or (617)
801-6888 (international), passcode# 26350236.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information about Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.